SearchPublisher and Institutes
You are here: Home :: Area NEM :: Medical science :: Human medicine
Ya-Huey Chen, Hua-Lin Wu, Ching Li, Yi-Hsien Huang, Chi-Wu Chiang, Ming-Ping Wu, Li-Wha Wu
Anti-angiogenesis mediated by angiostatin K13, K14 and K14.5. Involvement of p53, FasL, AKT and mRNA deregulation
Keywords: Angiostatin, Endothelial cells, AKT, p53, FasL
The molecular mechanism mediated by multiple forms of angiostatin via acting on proliferating vascular endothelium remains elusive. To address whether three forms of angiostatin, K13, K14 or K14.5, utilized similar or distinct pathways to mediate anti-angiogenesis, we adopted an adenoviral expression system to express secretable angiostatin molecules for CM collection. The anti-angiogenic activity of K13, K14 or K14.5 was confirmed by using proliferation, migration, tube formation and apoptotic assays of human endothelial cells. These angiostatin molecules at comparable expression level inhibited various in vitro angiogenesis assays with some variations. Furthermore, K13, K14 or K14.5 increased the expression of p53 protein and its downstream effectors, enhanced FasL-mediated signaling pathways, and decreased activation of AKT. At least three different receptors, Fas, integrin v3 and ATP synthase, were involved in the anti-angiogenic action of angiostatin molecules. Besides, the expression of 189 genes at mRNA level was significantly altered by K13, K14 or K14.5. More than 70% of these genes participate in growth, inflammation, apoptosis, migration and extracellular matrix. Taken together, K13, K14 and K14.5, regardless of the number of kringles in the angiostatin molecules, mediated anti-angiogenesis via mostly similar pathways. We are the first to demonstrate the involvement of DAPK1 in the mediation of anti-angiogenesis by angiostatin.
Thrombosis and Haemostasis, Schattauer
Print ISSN: 0340-6245
Volume: 95, 04/2006
Pages: 668 - 677